Editas Medicine, Inc.

Equities

EDIT

US28106W1036

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
5.32 ^USD	+1.92%		-3.10%	-47.48%

Mar. 13	Transcript : Editas Medicine, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 02:05 PM
Feb. 29	Barclays Adjusts Price Target on Editas Medicine to $11 From $10, Maintains Equal-Weight Rating	MT

Editas Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

February 28, 2024 at 07:00 am EST

Editas Medicine, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 153.22 million compared to USD 220.43 million a year ago. Basic loss per share from continuing operations was USD 2.02 compared to USD 3.21 a year ago.

Diluted loss per share from continuing operations was USD 2.02 compared to USD 3.21 a year ago.

Latest news about Editas Medicine, Inc.

Transcript : Editas Medicine, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 02:05 PM	Mar. 13
Barclays Adjusts Price Target on Editas Medicine to $11 From $10, Maintains Equal-Weight Rating	Feb. 29	MT
Transcript : Editas Medicine, Inc., Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Editas Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Editas Medicine, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
North American Morning Briefing : Stock Futures -2-	Feb. 21	DJ
Transcript : Editas Medicine, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 04:30 PM	Jan. 09
RBC Boosts Price Target on Editas Medicine to $11 From $8, Keeps Sector Perform Rating	Jan. 03	MT
Editas Medicine Strikes License Deal With Vertex Pharmaceuticals -- Update	Dec. 13	DJ
Editas Medicine Enters Licensing Deal With Vertex Pharmaceuticals for Cas9	Dec. 13	MT
Editas Medicine Strikes License Deal With Vertex Pharmaceuticals	Dec. 13	DJ
Editas Medicine and Vertex Pharmaceuticals Enter into Non-Exclusive License Agreement for Cas9	Dec. 13	CI
Truist Adjusts Editas Medicine's Price Target to $20 From $15, Maintains Buy Rating	Dec. 12	MT
Editas Medicine, Inc. Announces New EDIT-301 Safety And Efficacy Data In 17 Patients, Presented At The American Society Of Hematology Annual Meeting And In A Company-Sponsored Webinar	Dec. 11	CI
Transcript : Editas Medicine, Inc. - Special Call	Dec. 11
Transcript : Editas Medicine, Inc., Q3 2023 Earnings Call, Nov 03, 2023	Nov. 03
Editas Medicine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 03	CI
North American Morning Briefing : S&P 500 Futures -2-	Nov. 03	DJ
Editas Medicine, Inc. to Present Clinical Data from the Rubber and Edithal Trials of Edit-301 At the Ash 2023 Annual Meeting and in A Company-Sponsored Webinar	Nov. 02	CI
North American Morning Briefing : Google Parent's -2-	23-10-25	DJ
Will the AI bet pay off?	23-10-24
Citigroup Upgrades Editas Medicine to Buy From Neutral, Price Target is $11	23-10-24	MT
ANALYST RECOMMENDATIONS : Dollar General, On Holding, Rio Tinto, Solaredge, Thermo Fisher...	23-10-24
JPMorgan Upgrades Editas Medicine to Neutral From Underweight, Price Target is $8	23-10-18	MT
North American Morning Briefing : Geopolitical -2-	23-10-18	DJ

Chart Editas Medicine, Inc.

Duration

Period

More charts

Company Profile

Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide ribonucleic acid (RNA) molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. It is engaged in the development of vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, reni-cel, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta thalassemia (TDT).

Sector

Biotechnology & Medical Research

Calendar

2024-04-30 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Editas Medicine, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

5.32 USD

Average target price

15.4 USD

Spread / Average Target

+189.47%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
EDITAS MEDICINE, INC.	-47.48%	437M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research